黛力新联合乙吗噻嗪治疗右室流出道特发性室性期前收缩的疗效和安全性研究

Effects of Deanxit Combined with Moricizine in Treating Idiopathic Ventricular Premature Beats Originating from the Right Ventricular Outflow Tract

目的对比分析黛力新联合乙吗噻嗪和单用乙吗噻嗪治疗右室流出道特发性室性期前收缩(IVPBOR-VOT)的疗效和安全性。方法以2008年1月—2010年10月在温岭市第一人民医院确诊的IVPBORVOT患者为研究对象,随机分为试验组(服用黛力新和乙吗噻嗪)和对照组(服用乙吗噻嗪),治疗前和治疗后4周进行动态心电图检查和心悸、失眠、胸闷、头昏/头痛、乏力等症状评分,观察两组患者治疗前后室性期前收缩和症状的改善情况,并记录不良反应。结果共294例患者纳入本研究,试验组150例,其中男69例,女81例,平均年龄(48.8±17.8)岁,期前收缩次数(13 846±10 656)次/24 h;对照组144例,其中男65例,女79例,平均年龄(48.2±14.3)岁,期前收缩次数(15 550±10 001)次/24 h。两组在性别构成、年龄、室性期前收缩数量方面差异无统计学意义(P>0.05)。在室性期前收缩的改善方面,试验组显效48例,有效81例,无效21例,总有效率为86.00%;对照组显效35例,有效69例,无效40例,总有效率为72.22%,两组比较差异有统计学意义(χ2=9.807,P=0.020)。在心悸、失眠、胸闷、头昏/头痛、乏力等症状的改善方面,试验组显效61例,有效74例,无效15例,总有效率为90.00%;对照组显效39例,有效59例,无效46例,总有效率为68.06%,两组比较差异有统计学意义(χ2=24.818,P=0.000)。结论黛力新联合乙吗噻嗪治疗IVPBORVOT具有较好疗效,且不增加不良反应。

Objective To explore the efficacy and safety of deanxit and moricizine combination and moricizine alone in treating idiopathic ventricular premature beats originating from the right ventricular outflow tract（IVPBORVOT）.Methods Patients diagnosed with IVPBORVOT from the First People′s Hospital of Wenling between Jan.2008 and Oct.2010 were randomly divided into the observation group（deanxit and moricizine combination） and the control group（moricizine alone）.Dynamic electrocardiogram and symptom scores（including cardiopalmus,insomnia,chest distress,dizziness/ headache and malaise） were evaluated both before and 4 weeks after treatment.Symptoms of ventricular premature beats were compared before and after treatment.Adverse effects were recorded.Results A total of 294 cases were enrolled in this study.The observation group included 150 cases（69 males,81 females;aged（48.8±17.8）;premature beats：（13 846±10 656）times/24 h）.The control group included 144 cases（65 males,79 females;aged（48.2±14.3）;premature beats：（15 550±10 001） times/24 h）.No significant differences were noted concerning age,gender,and number of ventricular premature beats before treatment（P0.05）.The observation group showed significantly higher effective rate compared with the control group in terms of ventricular premature beats improvement（evidently effective：48 vs 35;effective：81 vs 69;invalid：21 vs 40;total effective rate：86.00% vs72.22%;χ2=9.807,P=0.020）.The observation group showed significantly higher effective rate compared with the control group in terms of cardiopalmus,insomnia,chest distress,dizziness/ headache and malaise improvement（evidently effective：61 vs 39;effective：74 vs 59;invalid：15 vs 46;total effective rate：90.00% vs 68.06%;χ2=24.818,P=0.000）.Conclusion Combined deanxit and moricizine display better curative effects in IVPBORVOT patients without extra adverse effects.